JPMorgan raised the firm’s price target on Cigna to $435 from $432 and keeps an Overweight rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Fly Insider: Transocean, AECOM among week’s notable insider trades
- Cigna price target raised to $400 from $370 at Oppenheimer
- Cigna price target raised to $400 from $384 at Cantor Fitzgerald
- CI Earnings: Cigna Rises on Strong Q1 Performance
- Cigna raises FY24 adjusted EPS view to $28.40 from $28.25, consensus $28.43